Grufity logoGrufity logo

Shockwave Medical Inc Stock Research

SWAV

216.83USD+2.67(+1.25%)Market Closed

Market Summary

USD216.83+2.67
Market Closed
1.25%

SWAV Alerts

SWAV Stock Price

SWAV RSI Chart

SWAV Valuation

Market Cap

7.2T

Price/Earnings (Trailing)

82.2K

Price/Sales (Trailing)

16.8K

EV/EBITDA

76.4K

Price/Free Cashflow

104.4K

SWAV Price/Sales (Trailing)

SWAV Profitability

EBT Margin

24.67%

Return on Equity

42.24%

Return on Assets

33.43%

Free Cashflow Yield

10e-4%

SWAV Fundamentals

SWAV Revenue

Revenue (TTM)

489.7M

Revenue Y/Y

71.09%

Revenue Q/Q

9.67%

SWAV Earnings

Earnings (TTM)

216.0M

Earnings Y/Y

988.79%

Earnings Q/Q

302.57%

Price Action

52 Week Range

113.36320.54
(Low)(High)

Last 7 days

1.2%

Last 30 days

14.6%

Last 90 days

5.5%

Trailing 12 Months

4.6%

SWAV Financial Health

Current Ratio

7.25

Debt/Equity

0.03

Debt/Cashflow

7.93

SWAV Investor Care

Shares Dilution (1Y)

2.27%

Diluted EPS (TTM)

5.7

Peers (Alternatives to Shockwave Medical)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
108.0B
18.4B
9.81% 7.15%
45.81
5.86
7.84% 18.25%
89.4B
6.2B
12.38% -15.32%
67.62
14.37
8.97% -22.43%
71.6B
12.7B
6.86% 12.96%
102.61
5.65
6.68% -32.95%
70.1B
19.0B
7.04% -3.24%
43.54
3.69
-0.43% -8.78%
50.3B
5.4B
3.61% -29.72%
33.07
9.35
2.86% 1.25%
MID-CAP
7.2T
489.7M
14.55% 4.57%
82.2K
16.8K
106.51% 2464.23%
10.6B
847.1M
7.86% 25.46%
-5.3K
12.54
13.32% -137.89%
5.6B
1.0B
-2.14% -23.23%
32.76
5.52
6.76% 24.45%
3.7B
410.9M
4.99% -21.24%
-32.24
9.11
27.29% -14.60%
2.6B
801.2M
10.62% -65.08%
-27.7
3.27
14.00% -707.69%
SMALL-CAP
1.7B
350.9M
3.38% 35.65%
-10.93
4.74
44.26% -5.42%
1.5B
138.6M
-18.17% -5.23%
-27.28
10.83
36.62% -10.44%
1.4B
820.0M
5.46% -11.22%
27.4
1.69
10.13% 701.59%
833.4M
239.8M
0.46% -12.12%
-22.01
3.47
-4.74% -31.15%

Financials for Shockwave Medical

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue13.9%490430364299237
Gross Profit14.9%425370310252196
  S&GA Expenses6.8%162152138123111
  R&D Expenses12.4%82.0073.0066.0057.0051.00
EBITDA34.8%12895.0061.0034.00-4.14
EBITDA Margin18.3%0.26*0.22*0.17*0.11*-0.02*
Earnings Before Taxes35.4%12189.0056.0029.00-8.84
EBT Margin18.9%0.25*0.21*0.15*0.10*-0.04*
Interest Expenses55.5%2.001.001.001.001.00
Net Income145.4%21688.0055.0029.00-9.14
Net Income Margin115.4%0.44*0.20*0.15*0.10*-0.04*
Free Cahsflow33.7%93.0069.0048.0023.003.00
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets35.8%646476417373346
  Current Assets16.2%459395352310286
    Cash Equivalents22.5%15712810066.0089.00
  Inventory8.9%75.0069.0060.0053.0043.00
  Net PPE22.6%48.0039.0032.0028.0024.00
Liabilities12.4%135120112105104
  Current Liabilities16.9%63.0054.0066.0051.0052.00
  Long Term Debt-14.8%15.0017.0017.0017.00-
    LT Debt, Current-100.0%-6.00---
    LT Debt, Non Current130.6%15.006.009.0012.00-
Shareholder's Equity43.7%511356305268242
  Retained Earnings79.3%-36.81-177-212-238-252
  Additional Paid-In Capital2.6%549535519507495
Accumulated Depreciation-6.00----
Shares OutstandingNaN%--35,82635,587-
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations36.7%11886.0061.0034.0015.00
  Share Based Compensation11.0%45.0040.0036.0032.0027.00
Cashflow From Investing-24.4%-62.15-49.98-49.48-28.0826.00
Cashflow From Financing233.1%13.004.006.003.00-2.45

Risks for SWAV

What is the probability of a big loss on SWAV?

98.1%


Probability that Shockwave Medical stock will be more than 20% underwater in next one year

71.5%


Probability that Shockwave Medical stock will be more than 30% underwater in next one year.

61.2%


Probability that Shockwave Medical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SWAV drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Shockwave Medical was unfortunately bought at previous high price.

Drawdowns

Returns for SWAV

Cumulative Returns on SWAV

87.0%


3-Year Cumulative Returns

Which funds bought or sold SWAV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-29
Diametric Capital, LP
reduced
-25.35
-773,203
952,797
0.46%
2023-03-23
MetLife Investment Management, LLC
reduced
-1.35
-3,104,080
8,368,530
0.07%
2023-03-17
American Portfolios Advisors
new
-
1,161,220
1,161,220
0.05%
2023-03-15
B. Riley Wealth Advisors, Inc.
new
-
339,051
339,051
0.01%
2023-03-10
BAILLIE GIFFORD & CO
reduced
-11.8
-38,153,300
71,529,700
0.07%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-13.55
-20,004,200
35,448,800
0.04%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
new
-
411,220
411,220
0.06%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-3.8
-81,000
197,000
-%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
sold off
-100
-
-
-%
2023-02-28
Voya Investment Management LLC
added
7.81
-1,872,040
7,357,960
0.01%

1–10 of 47

Latest Funds Activity

Are funds buying SWAV calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own SWAV
No. of Funds

Shockwave Medical News

Nasdaq

Is the Options Market Predicting a Spike in Shockwave Medical ....

Nasdaq,
45 hours ago

Investor's Business Daily

Yahoo Finance

The Motley Fool

Investopedia

Schedule 13G FIlings of Shockwave Medical

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
2.8%
1,012,393
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Jan 23, 2023
blackrock inc.
12.7%
4,572,659
SC 13G/A
Jan 10, 2023
vanguard group inc
10.22%
3,694,931
SC 13G/A
Jul 08, 2022
blackrock inc.
12.1%
4,313,553
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
8.7%
3,077,252
SC 13G/A
Feb 14, 2022
gilder gagnon howe & co llc
3.9%
1,384,358
SC 13G/A
Feb 03, 2022
blackrock inc.
7.7%
2,716,533
SC 13G/A
Jan 10, 2022
fmr llc
-
0
SC 13G/A
Nov 09, 2021
jpmorgan chase & co
3.4%
1,209,265
SC 13G/A

SWAV Fair Value

Shockwave Medical fair value in different scenarios

The table shows the Fair Value estimates for Shockwave Medical for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

0.03

-99.99%

0.03

-99.99%

0.07

-99.97%

0.11

-99.95%

0.19

-99.91%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Shockwave Medical Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Shockwave Medical

View All Filings
Date Filed Form Type Document
Mar 28, 2023
4
Insider Trading
Mar 22, 2023
4
Insider Trading
Mar 21, 2023
4
Insider Trading
Mar 21, 2023
4/A
Insider Trading
Mar 14, 2023
4
Insider Trading
Feb 28, 2023
4
Insider Trading
Feb 27, 2023
10-K
Annual Report
Feb 27, 2023
S-8
Employee Benefits Plan
Feb 24, 2023
4
Insider Trading
Feb 23, 2023
4
Insider Trading

Latest Insider Trading transactions for SWAV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-27
Zacharias Isaac
sold
-862,760
215
-4,000
president, cco
2023-03-20
PUCKETT DAN
sold
-220,814
200
-1,100
chief financial officer
2023-03-20
WATKINS FRANK T
acquired
6,588
2.196
3,000
-
2023-03-20
PUCKETT DAN
acquired
18,700
17.00
1,100
chief financial officer
2023-03-20
WATKINS FRANK T
sold
-602,015
200
-3,000
-
2023-03-10
Zacharias Isaac
sold (taxes)
-102,790
190
-541
president, cco
2023-02-27
Zacharias Isaac
sold
-754,040
188
-4,000
president, cco
2023-02-23
Sainz Maria
sold
-139,732
193
-724
-
2023-02-22
Phung Trinh
sold
-120,378
188
-640
vp, finance
2023-02-22
PUCKETT DAN
sold
-700,244
191
-3,653
chief financial officer

1–10 of 50

Douglas E. Godshall
660
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

SWAV Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Product revenue$ 489,733,000$ 237,146,000$ 67,789,000
Cost of revenue:   
Cost of product revenue64,996,00041,438,00020,991,000
Gross profit424,737,000195,708,00046,798,000
Operating expenses:   
Research and development81,679,00050,544,00036,926,000
Sales and marketing161,995,000111,288,00051,672,000
General and administrative56,929,00034,747,00023,863,000
Total operating expenses300,603,000196,579,000112,461,000
Income (loss) from operations124,134,000(871,000)(65,663,000)
Loss from equity method investment(2,475,000)(6,286,000)0
Interest expense(1,886,000)(1,096,000)(1,212,000)
Other income (expense), net1,055,000(582,000)1,256,000
Net income (loss) before taxes120,828,000(8,835,000)(65,619,000)
Income tax (benefit) provision(95,168,000)301,00080,000
Net income (loss)215,996,000(9,136,000)(65,699,000)
Other comprehensive income (loss)   
Unrealized loss on available-for-sale securities, net of tax(659,000)(211,000)(5,000)
Adjustment for net gain realized and included in other income, net(6,000)0(21,000)
Total comprehensive income (loss)$ 215,331,000$ (9,347,000)$ (65,725,000)
Net income (loss) per share   
Basic (USD per share)$ 6.02$ (0.26)$ (1.99)
Diluted (USD per share)$ 5.70$ (0.26)$ (1.99)
Denominator:   
Basic (in shares)35,900,73835,098,13033,088,095
Diluted (in shares)37,881,59035,098,13033,088,095
Revenue, Product and Service [Extensible Enumeration]Product [Member]Product [Member]Product [Member]
Cost, Product and Service [Extensible Enumeration]Product [Member]Product [Member]Product [Member]

SWAV Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
CURRENT ASSETS:  
Cash and cash equivalents$ 156,586$ 89,209
Short-term investments147,907111,772
Accounts receivable, net71,36637,435
Inventory75,11242,978
Prepaid expenses and other current assets8,2924,508
Total current assets459,263285,902
Operating lease right-of-use assets32,36527,496
Property and equipment, net48,15224,361
Equity method investment3,5125,987
Deferred tax assets97,5680
Other assets5,2291,936
TOTAL ASSETS646,089345,682
CURRENT LIABILITIES:  
Accounts payable6,7213,520
Debt, current portion05,500
Accrued liabilities55,37540,870
Lease liability, current portion1,2781,738
Total current liabilities63,37451,628
Lease liability, noncurrent portion34,92828,321
Debt, noncurrent portion24,19811,630
Related party contract liability, noncurrent portion12,27312,273
TOTAL LIABILITIES134,773103,852
Commitments and contingencies (Note 6)
STOCKHOLDERS’ EQUITY:  
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; No shares issued and outstanding as of December 31, 2022 and 202100
Common stock, $0.001 par value per share; 281,274,838 shares authorized; 36,235,546 and 35,444,472 issued and outstanding as of December 31, 2022 and 20213635
Additional paid-in capital548,960494,806
Accumulated other comprehensive loss(867)(202)
Accumulated deficit(36,813)(252,809)
TOTAL STOCKHOLDERS’ EQUITY511,316241,830
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 646,089$ 345,682